7. The Economics of Prophylaxis: Does Prophylaxis with Clotting Factor Represent Value for Money?

  1. Emérito-Carlos Rodríguez-Merchán MD, PHD2,3 and
  2. Leonard A. Valentino MD4
  1. Alec Miners BSc (Hons), MSc, PhD

Published Online: 12 MAY 2011

DOI: 10.1002/9781119979401.ch7

Current and Future Issues in Hemophilia Care

Current and Future Issues in Hemophilia Care

How to Cite

Miners, A. (2011) The Economics of Prophylaxis: Does Prophylaxis with Clotting Factor Represent Value for Money?, in Current and Future Issues in Hemophilia Care (eds E.-C. Rodríguez-Merchán and L. A. Valentino), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781119979401.ch7

Editor Information

  1. 2

    Department of Orthopedic Surgery and Hemophilia Unit, La Paz University Hospital, Spain

  2. 3

    School of Medicine, Autonomous University, Madrid, Spain

  3. 4

    Hemophilia and Thrombophilia Center, Rush University Medical Center, Chicago, IL, USA

Author Information

  1. London School of Hygiene and Tropical Medicine, London, UK

Publication History

  1. Published Online: 12 MAY 2011
  2. Published Print: 13 MAY 2011

ISBN Information

Print ISBN: 9780470670576

Online ISBN: 9781119979401

SEARCH

Keywords:

  • economics;
  • economic evaluation;
  • prophylaxis;
  • hemophilia;
  • clotting factor;
  • cost

Summary

Hemophilia is a rare lifelong disease for which there is no cure. The mainstay of treatment is replacement therapy with clotting factor. Treatment is often given on-demand, following hemorrhage, or prophylactically, in an attempt to prevent bleeding and musculoskeletal problems in the first instance. Evidence suggests that prophylaxis is the more effective treatment, however, it is costly to provide. Health economics as a discipline emphasizes the ratio of costs to benefits, rather than the total costs of treatment alone. Thus, costly treatments can be justified on economic grounds if they also generate sufficient improvements in health. The aim of this chapter is to review the economics literature with respect to prophylaxis with a view to critiquing it and coming to a conclusion about whether or not prophylaxis represents value for money.